These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 33327495

  • 1. HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma.
    Hüser L, Kokkaleniou MM, Granados K, Dworacek J, Federico A, Vierthaler M, Novak D, Arkhypov I, Hielscher T, Umansky V, Altevogt P, Utikal J.
    Cancers (Basel); 2020 Dec 14; 12(12):. PubMed ID: 33327495
    [Abstract] [Full Text] [Related]

  • 2. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
    Wang X, Qu H, Dong Y, Wang G, Zhen Y, Zhang L.
    Cancer Biomark; 2018 Dec 14; 23(1):67-77. PubMed ID: 30010109
    [Abstract] [Full Text] [Related]

  • 3. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
    Hüser L, Sachindra S, Granados K, Federico A, Larribère L, Novak D, Umansky V, Altevogt P, Utikal J.
    Int J Cancer; 2018 Dec 15; 143(12):3131-3142. PubMed ID: 29905375
    [Abstract] [Full Text] [Related]

  • 4. Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells.
    Su Y, Yu Y, He D, Zhang J, Wang Z, Sun P, Chen Z.
    Int J Clin Exp Pathol; 2018 Dec 15; 11(5):2550-2560. PubMed ID: 31938368
    [Abstract] [Full Text] [Related]

  • 5. Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAFV600E mutation.
    Wang K, Li Y, Song N, Che X, Hou K, Xu L, Bai M, Wang Q, Wang Y, Zhou Y, Cao M, Liu Y, Zhang J.
    J Cell Biochem; 2019 Apr 15; 120(4):5315-5325. PubMed ID: 30320916
    [Abstract] [Full Text] [Related]

  • 6. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.
    Mol Cancer Ther; 2014 Feb 15; 13(2):353-63. PubMed ID: 24398428
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G.
    Cancer Res; 2012 Feb 15; 72(4):969-78. PubMed ID: 22205714
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.
    J Clin Oncol; 2013 May 10; 31(14):1767-74. PubMed ID: 23569304
    [Abstract] [Full Text] [Related]

  • 14. Vemurafenib.
    Garbe C, Abusaif S, Eigentler TK.
    Recent Results Cancer Res; 2014 May 10; 201():215-25. PubMed ID: 24756795
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK.
    Oncotarget; 2015 Dec 01; 6(38):40535-56. PubMed ID: 26497853
    [Abstract] [Full Text] [Related]

  • 16. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
    Sandri S, Faião-Flores F, Tiago M, Pennacchi PC, Massaro RR, Alves-Fernandes DK, Berardinelli GN, Evangelista AF, de Lima Vazquez V, Reis RM, Maria-Engler SS.
    Pharmacol Res; 2016 Sep 01; 111():523-533. PubMed ID: 27436149
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC.
    Oncotarget; 2016 May 24; 7(21):30907-23. PubMed ID: 27127178
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAFV600E inhibitor-resistant metastatic melanoma cells.
    Martin S, Dudek-Peric AM, Garg AD, Roose H, Demirsoy S, Van Eygen S, Mertens F, Vangheluwe P, Vankelecom H, Agostinis P.
    Autophagy; 2017 Sep 02; 13(9):1512-1527. PubMed ID: 28722539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.